We are live on ! Find out more
MSLE icon

Satellos Bioscience

30 hedge funds and large institutions have $64.7M invested in Satellos Bioscience in 2026 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

37% more capital inflows, than outflows

Capital inflows: $5.37M | Capital outflows: $3.93M

15% more funds holding

Funds holding: 26 → 30 (+4)

0.06% more ownership

Funds ownership: 36.89% → 36.95% (+0.06%)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
30
Holders Change
+4
Holders Change %
+15.38%
% of All Funds
0.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
6
Reduced
10
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MSLE Hedge Fund Activity: Q3 2026 in Review

30 of the 8,167 institutional investors tracked by Wall St. Rank reported a position in Satellos Bioscience (MSLE) for Q3 2026, worth a combined $64.7M — up 8.7% from $59.6M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MSLE positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Saturn V Capital Management, adding an estimated $1.55M. The largest seller was Avidity Partners Management, cutting an estimated $2.08M.

  • 30 institutional investors held Satellos Bioscience (MSLE) as of Q3 2026, up from 26 in Q2 2026.
  • Funds reported $64.7M of Satellos Bioscience stock for Q3 2026, up 8.7% quarter-over-quarter.
  • 6 funds opened new Satellos Bioscience positions in Q3 2026 and 2 closed out, a net change of +4 holders.
  • The largest Satellos Bioscience buyer in Q3 2026 was Saturn V Capital Management, an estimated $1.55M added.
  • The largest Satellos Bioscience seller in Q3 2026 was Avidity Partners Management, an estimated $2.08M sold.

Based on aggregated 13F filings for Q3 2026.